ArticleJournal of Alzheimer's disease reports
Clarifying blood-based brain-derived neurotrophic factor measurement in Alzheimer's disease research: A call for pre-analytic standardization.
Article in Journal of Alzheimer's disease reports. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Hypoxia preconditioned serum (HPS) and platelet-rich plasma (PRP) promote proliferation, neurite network formation, and neurite elaboration in N2a cells.Frontiers in bioengineering and biotechnology · 2026Article
- The prognostic potential of circulating BDNF levels and its polymorphisms in age-related cognitive impairment and neurodegeneration.Frontiers in aging neuroscience · 2026Review
- Serum BDNF in subacute stroke: effects of a four-week aerobic exercise intervention in the PHYS-STROKE trial.Frontiers in stroke · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The study by Kueck et al. rigorously addresses the complex pre-analytical and biological confounds underlying blood-based brain-derived neurotrophic factor (BDNF) measurement in Alzheimer's disease (AD) research. By directly comparing platelet-rich plasma and platelet-poor plasma, it distinguishes free-circulating from platelet-stored BDNF and their associations with core AD biomarkers. Findings support BDNF as a potential compensatory marker in early cognitive impairment and emphasize the critical need for biomarker-specific pre-analytic standardization protocols. This commentary contextualizes the work within existing inconsistencies and outlines key recommendations for standardizing blood-based BDNF measurements to ensure reproducibility, potential clinical utility, and translational relevance.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.